RLS is quite prevalent so the treatable population is there. and if pfizer didnt think there was a reasonable market why run the trials (unless you can argue to garner off label use??)
i think the main driver of them not formally seeking approval and actively marketing is cost - lyrica 300mg a day is over 300 dollars a month - triple the cost of horizant. that or there is a wrinkle in the data jmo
Market Data 
Markets 
AI
